08/06/2026
Today, we publish a new position paper calling for equitable and timely access to and , the first disease-modifying therapies for disease authorised in the European Union.
Developed following consultation with national member associations, the European Working Group of People with Dementia and the European Dementia Carers Working Group , the paper sets out five areas of concern and calls for concrete action from governments, health technology assessment (HTA) bodies, manufacturers and the research community.
The five key concerns identified are:
โ Meaningful benefit is shaped by individual circumstances and lived experience, and the significant societal cost of dementia, including the often-invisible burden on informal carers, is insufficiently captured in many assessment models. The perspectives of people living with Alzheimer's disease, their carers and the patient organisations that represent them must be genuinely and substantively incorporated in assessments from the outset.
โ Every person with Alzheimer's disease deserves access to a timely and accurate diagnosis, independently of whether treatment is available or reimbursed. Diagnostic infrastructure gaps should not be used as a justification for withholding access to authorised therapies, and investment in diagnostic capacity is essential to prepare for future treatments.
โ People living with Alzheimer's disease deserve the opportunity to make an informed, supported decision on treatment with their doctors and families, based on clear and balanced information about expected benefits, risks and uncertainties.
โ The current absence of reimbursement across most of Europe is deepening inequity. Access is primarily determined by wealth and geography rather than clinical need, compounding disparities that extend beyond treatment to diagnosis, support and care.
โ Managed access frameworks and pilot programmes, of the kind already established for cancer and other serious conditions, offer a practical and proportionate pathway to treatment while real-world evidence continues to develop.
https://bit.ly/AE_AntiAmyloidTreatmentAccess
